Better Dairy announces self-affirmed GRAS conclusion for lactopontin
The public release leaves detailed intended-use conditions unspecified, so formulation teams still need the scope behind the company’s announcement.
All publications
Find the reporting, analysis and practical guides that matter to your work.
News · Guides & tools · How our formats work
Browse publications
Publications in date order, newest first.
IMIO reports $12m raise for planned Chicago operations
Its process description makes the link between stored microbial batches and controlled field outcomes a specific diligence question.
Kinish reports JPY490m first close for Series A
The funding spans conventional-rice ice cream sales and a separate casein research programme, giving investors distinct milestones to assess.
GLP-1 review reports lower energy intake, measured mostly at controlled meals
Most of the evidence comes from meals served under test conditions. What people using these medicines eat day to day is much less settled, which limits what a product brief can take from it.
US cohort finds no overall association between ultra-processed food intake and colorectal cancer
Published on 15 October, the NIH-AARP analysis measured intake differently from a 2022 study that associated higher intake with higher risk in men. Neither result supports a claim about a specific product.
Mycofeast says it has acquired New Zealand lactoferrin developer Daisy Lab
The Oxford-headquartered group links the New Zealand developer with engineering in California and a former brewery it is converting in Poland. The announcements give no deal terms or commercial output figures.
Canada announces C$50m for CFIN to help food processors adopt automation and AI
The government expects more than 200 small and medium-sized processors to receive support. Until delivery terms appear, R&D teams can prepare the measurements a funded trial would need.
GLP-1 food: start with what people actually eat
Your formula can hit its protein target while the product misses the eating occasion. Here is the question I would put at the top of the brief.
FrieslandCampina sets out small-portion protein concepts for GLP-1 users
A 20 g protein shot in 100 ml gives R&D teams a concrete brief. The supplier specifications still need a comparison with what intended users finish and choose again.
EU record lists defatted olive pulp fruit powder as non-novel
The 13 October publication describes a food-supplement use. Keep the material, process and intended use attached to the finding.
Which claim in your pitch can the evidence actually carry?
Match a pitch claim to its actual evidence. Two worked exercises help food biotech teams show progress without implying proof they do not have.
Which costs can you cut without losing the evidence you need?
Free account: turn a proposed spending change into a commitment record with cash timing, evidence, dependencies and a review trigger.